About Likarda
Likarda is a company based in Kansas City (United States) founded in 2012. Likarda has raised $4 million across 2 funding rounds from investors including HHS. The company has 8 employees as of December 31, 2022. Likarda offers products and services including Core-Shell Spherification, Microencapsulation, and ViscoBeads. Likarda operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Kansas City, United States
- Employees 8 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Likarda, Llc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4 M (USD)
in 2 rounds
-
Latest Funding Round
$256.34 K (USD), Grant
Sep 07, 2021
- Investors
-
Employee Count
8
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Likarda
Likarda offers a comprehensive portfolio of products and services, including Core-Shell Spherification, Microencapsulation, and ViscoBeads.
Method for encapsulating cells to optimize therapy delivery and efficacy.
Process to protect cell therapies from immune systems using hydrogels.
Customizable beads for targeted cell therapy administration.
People of Likarda
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Likarda
Likarda has successfully raised a total of $4M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $256.34 thousand completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Likarda
Likarda has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Likarda
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Likarda
Investment portfolio details for Likarda
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Likarda
Detailed financials for Likarda
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Likarda Comparisons
Peer comparison for Likarda
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Likarda
Likarda operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Likarda
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Likarda
Complete news archive for Likarda
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Likarda
Likarda was founded in 2012 and raised its 1st funding round 5 years after it was founded.
Likarda is headquartered in Kansas City, United States. It is registered at Kansas City, Missouri, United States.
Likarda is a funded company, having raised a total of $4M across 2 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Likarda is 8.
Likarda is creating 3D cell culturesminiaturized organs from their proprietary cell culture systems which will have potential applications in drug discovery, development, cell-based transplantation, and regenerative medicine. The company offers integrated early-stage discovery research along with consultative and analytical services. The company has created Kanslet, a reaggregated islet capable of producing insulin (from a donor pancreas) which can be transplanted into dogs and cats for treating diabetes. Kanslets can also be used for secondary drug testing and multiple studies have been published already in support of the technology.
Likarda's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Likarda offers Core-Shell Spherification, Microencapsulation, and ViscoBeads.
Likarda has 1 investor. Key investors include HHS.